Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · Hematology, Oncology, Internal MedicineMedium impact

08.02.30, Imetelstat (Rytelo™)

Act
by May 19, 2025
Effective date
May 19, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross has published a new commercial medical policy (08.02.30a, effective 05/19/2025) establishing coverage criteria for imetelstat (Rytelo®) injection for treating transfusion-dependent symptomatic anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes. The policy requires documentation of MDS diagnosis, specific transfusion history, validated risk scoring, cytogenetic markers, and prior treatment failures with ESA, luspatercept-aamt, or other specified agents before coverage is approved.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by May 19, 2025 · 6 steps
01Billing and prior authorization teams must implement coverage criteria for HCPCS code J0870 (imetelstat injection).
02Update authorization templates and documentation requirements to verify: (1) MDS diagnosis confirmed by bone marrow aspirate/biopsy, (2) transfusion dependence (≥4 RBC units in 8 weeks with pretransfusion hemoglobin ≤9.0 g/dL), (3) lower-risk disease per IPSS-R scoring, (4) absence of del(5q), and (5) documented prior treatment failures/non-response to ESA, luspatercept-aamt, IST, or other specified agents per policy hierarchy.
03Providers must submit complete hematology work-up including IPSS-R risk classification, cytogenetics, ring sideroblast percentage, serum erythropoietin levels, and prior medication trials.
04Claims submitted without this documentation will be denied.
05Update provider education materials and EMR templates to include these requirements.
06Coordinate with hematology/oncology practices to ensure they understand multi-line therapy sequencing requirements before imetelstat approval.

Codes mentioned

J0870

Original notice

08.02.30, Imetelstat (Rytelo™)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.177a, Imetelstat (Rytelo®)MediumEffective Jun 29, 2026 · Pharmacy08.02.30a, Imetelstat (Rytelo®)MediumEffective Jun 29, 2026 · PharmacyMA08.177, Imetelstat (Rytelo™)MediumEffective May 19, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesHematologyOncologyInternal MedicineCode J0870

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account